Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Carcinoma, Renal Cell 6Kidney Neoplasms 4Leukemia, Myeloid, Chronic-Phase 3Carcinoma, Hepatocellular 3Unspecified Adult Solid Tumor, Protocol Specific 2Polycythemia Vera 2Ovarian Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Leukemia 2Hepatitis B, Chronic 2Fallopian Tube Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Thrombocytosis 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Osteosarcoma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplasms 1

Interventions

Rituximab 344Cyclophosphamide 317fludarabine phosphate 142Etoposide 139Peripheral Blood Stem Cell Transplantation 124fludarabine 112Filgrastim 112Mycophenolic Acid 98Melphalan 98Whole-Body Irradiation 90Vincristine 90Busulfan 87Cytarabine 85Doxorubicin 79Cyclosporine 76Tacrolimus 75Radiotherapy 75Prednisone 73Bendamustine Hydrochloride 72Granulocyte Colony-Stimulating Factor 66Methotrexate 65Antilymphocyte Serum 56Carmustine 54Dexamethasone 50Gemcitabine 48Lenalidomide 46Bortezomib 43venetoclax 41ibritumomab tiuxetan 37obinutuzumab 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × peginterferon alfa-2b × Clear all
NCT00574730 2023-09-14

CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma

University of Nebraska

Phase NA Completed
27 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡